{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:06:28Z","timestamp":1752282388900,"version":"3.40.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Patients with hematological malignancies are at high-risk of Clostridium difficile infection (CDI). Oral vancomycin is a first-line treatment for CDI. Vancomycin has been widely reported to induce flushing syndrome (also known as Red man syndrome), a well-known hypersensitivity reaction mostly occurs after intravenous administration. However, a few cases of flushing syndrome due to oral vancomycin have been reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We reported a case of the 68-year-old male with Multiple Myeloma contracted suspected CDI during chemotherapy, oral vancomycin (125\u2009mg po q6h) was initiated for CDI. Approximately 24 hours after receiving oral vancomycin, the patient developed vancomycin flushing syndrome with facial flushing and an erythematous rash on the abdomen and back, despite normal vancomycin duration and renal function (no obvious risk factors).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The patient was diagnosed with Oral vancomycin induced flushing syndrome. The symptoms resolved after withdrawal of vancomycin and 4 days of treatment with loratadine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Oral vancomycin-induced flushing syndrome is a rare complication that can occur in patients with CDI despite the absence of obvious risk factors. The underlying mechanism of oral vacomycin-induced flushing syndrome may be direct activation of mast cells following mast cell degranulation and histamine release via the MRGPRX2 receptor. However, this is just speculation and there are insufficient data, particularly in vivo data, to draw any conclusions. For patients with risk factors such as gastrointestinal pathology and renal insufficiency, monitoring of vancomycin serum concentration, mast cell degranulation, histamine release, and MRGPRX2 levels is recommended to avoid vancomycin flushing Syndrome, and vancomycin can still be used under supervision.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040640","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T20:02:38Z","timestamp":1732564958000},"page":"e40640","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Oral vancomycin induced flushing syndrome in a multiple myeloma patient: A case report and review of the literature"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2612-5517","authenticated-orcid":false,"given":"Min","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"},{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HeMei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"},{"name":"Department of Pharmacy, People\u2019s Hospital of Rizhao, Rizhao, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JunWei","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.05.001","article-title":"Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients.","volume":"171","author":"Haeusler","year":"2022","journal-title":"Eur J Cancer"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhin.2019.12.017","article-title":"Excess burden associated with Clostridioides difficile infection in haematological patients occurring during hospitalization with induction chemotherapy in the USA.","volume":"104","author":"Duhalde","year":"2020","journal-title":"J Hosp Infect"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/jac\/dkx005","article-title":"Risk factors and impact of Clostridium difficile recurrence on haematology patients.","volume":"72","author":"Scappaticci","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s10096-018-3316-5","article-title":"Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation.","volume":"37","author":"Salamonowicz","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1017\/ice.2017.48","article-title":"Risk of clostridium difficile infection in hematology-oncology patients colonized with toxigenic C. difficile.","volume":"38","author":"Cannon","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of clostridioides difficile infections.","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13223-018-0293-2","article-title":"Rash induced by enteral vancomycin therapy in an older patient in a long-term care ventilator unit: case report and review of the literature.","volume":"14","author":"Barron","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jocn.2018.01.044","article-title":"Red man syndrome caused by vancomycin powder.","volume":"50","author":"Nagahama","year":"2018","journal-title":"J Clin Neurosci"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/cells10051033","article-title":"Unlocking the non-IgE-mediated pseudo-allergic reaction puzzle with mas-related G-protein coupled receptor member X2 (MRGPRX2).","volume":"10","author":"Kumar","year":"2021","journal-title":"Cells"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/08968608231199735","article-title":"Vancomycin flushing reaction after intraperitoneal vancomycin: a case report.","volume":"44","author":"M\u00f6hlmann","year":"2024","journal-title":"Perit Dial Int"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"e32047","DOI":"10.1097\/MD.0000000000032047","article-title":"A typical case had rare immediate and delayed red man syndrome multiple times after norvancomycin injection: a case report.","volume":"101","author":"Zang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"e13371","DOI":"10.1097\/MD.0000000000013371","article-title":"Red man syndrome following the use of vancomycin-loaded bone cement in the primary total knee replacement: A case report.","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.krcp.2014.09.005","article-title":"Immunoglobulin E-mediated hypersensitivity reaction after intraperitoneal administration of vancomycin.","volume":"34","author":"Hwang","year":"2015","journal-title":"Kidney Res Clin Pract"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7326\/0003-4819-115-5-410","article-title":"Red man syndrome after oral vancomycin.","volume":"115","author":"Killian","year":"1991","journal-title":"Ann Intern Med"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/106002809402800505","article-title":"Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function.","volume":"28","author":"Bergeron","year":"1994","journal-title":"Ann Pharmacother"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1757-1626-1-111","article-title":"An elderly woman with \u201cRed Man Syndrome\u201d in association with oral vancomycin therapy: a case report.","volume":"1","author":"Bailey","year":"2008","journal-title":"Cases J"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"bcr03.2009.1705","DOI":"10.1136\/bcr.03.2009.1705","article-title":"Rare case of \u201cred man\u201d syndrome in a female patient treated with oral vancomycin for Clostridium difficile diarrhoea.","volume":"2009","author":"Nallasivan","year":"2009","journal-title":"BMJ Case Rep"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12691\/ajmcr-7-1-5","article-title":"Red Man Syndrome with oral vancomycin: a case report.","volume":"7","author":"Arroyo-Mercado","year":"2019","journal-title":"Am J Med Case Rep"},{"key":"R20-20250503","first-page":"c79","article-title":"Correction: Vancomycin flushing syndrome due to oral vancomycin in chronic kidney disease patients: a case report.","volume":"14","author":"Yadav","year":"2022","journal-title":"Cureus"},{"key":"R21-20250503","first-page":"13","article-title":"Vancomycin flushing syndrome following oral administration of vancomycin.","volume":"120","author":"Kapitza","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fped.2014.00055","article-title":"Red man syndrome following intraperitoneal vancomycin in a child with peritonitis.","volume":"2","author":"Domis","year":"2014","journal-title":"Front Pediatr"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s15010-019-01374-7","article-title":"Does oral vancomycin use necessitate therapeutic drug monitoring?","volume":"48","author":"Cimolai","year":"2020","journal-title":"Infection"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/phar.1538","article-title":"Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.","volume":"35","author":"Pettit","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1038\/s41598-018-29965-8","article-title":"MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia.","volume":"8","author":"Navin\u00e9s-Ferrer","year":"2018","journal-title":"Sci Rep"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00000542-200004000-00026","article-title":"Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mastcells.","volume":"92","author":"Veien","year":"2000","journal-title":"Anesthesiology"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/BF01976748","article-title":"Mechanisms of vancomycin-induced histamine release from rat peritoneal mast cells.","volume":"40","author":"Horinouchi","year":"1993","journal-title":"Agents Actions"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo allergic drug reactions.","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:34:08Z","timestamp":1746318848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":28,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040640","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}